Suven Pharmaceuticals Limited
Cohance Lifesciences Limited engage in the end-to-end contract development and manufacturing of intermediates and active pharmaceutical ingredients in India. The coampny offers active pharmaceutical ingredients and formulations for various applications; CDMO services, a flexible and custom solutions for challenging development and manufacturing needs; and clinical, analytical, and research servic… Read more
Suven Pharmaceuticals Limited (SUVENPHAR) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2023: 0.013x
Based on the latest financial reports, Suven Pharmaceuticals Limited (SUVENPHAR) has a cash flow conversion efficiency ratio of 0.013x as of December 2023.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₹255.04 Million) by net assets (₹19.81 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Suven Pharmaceuticals Limited - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Suven Pharmaceuticals Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Suven Pharmaceuticals Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Suven Pharmaceuticals Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hydsoft Technology Co. Ltd. A
SHE:301316
|
N/A |
|
Kaynes Technology India Limited
NSE:KAYNES
|
-0.046x |
|
Guangdong Mingyang Electric Co. Ltd. A
SHE:301291
|
N/A |
|
Scandic Hotels Group AB (publ)
ST:SHOT
|
0.572x |
|
J & J Snack Foods Corp
NASDAQ:JJSF
|
0.039x |
|
Perpetual Limited
PINK:PPTTF
|
0.119x |
|
Shantui Construction Machinery Co Ltd
SHE:000680
|
0.030x |
|
Dongguan Eontec Co Ltd
SHE:300328
|
-0.045x |
Annual Cash Flow Conversion Efficiency for Suven Pharmaceuticals Limited (2019–2025)
The table below shows the annual cash flow conversion efficiency of Suven Pharmaceuticals Limited from 2019 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | ₹18.41 Billion | ₹2.88 Billion | 0.157x | -10.44% |
| 2024-03-31 | ₹20.51 Billion | ₹3.58 Billion | 0.175x | -32.73% |
| 2023-03-31 | ₹17.35 Billion | ₹4.51 Billion | 0.260x | +20.26% |
| 2022-03-31 | ₹15.27 Billion | ₹3.30 Billion | 0.216x | -33.46% |
| 2021-03-31 | ₹11.81 Billion | ₹3.83 Billion | 0.325x | -34.05% |
| 2020-03-31 | ₹8.45 Billion | ₹4.16 Billion | 0.492x | +476.64% |
| 2019-03-31 | ₹5.90 Billion | ₹504.05 Million | 0.085x | -- |